Mar. 2, 2026
Merck, Pfizer's Drug Combo 'Rewrites the Standard of Care' in Bladder Cancer
The new data shows the combo therapy significantly improved survival and treatment response in a late-stage muscle-invasive bladder cancer study.
Feb. 28, 2026
New Immunotherapy Drug Shows Promise for Advanced Prostate Cancer
VIR-5500 shrinks tumors and reduces key cancer biomarker in clinical trial
Feb. 27, 2026
Blue Earth Diagnostics Announces Positive Results from Prostate Cancer Imaging Study
Head-to-head comparison shows POSLUMA has significantly lower urinary radioactivity than piflufolastat F 18
Feb. 27, 2026
ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naive Bladder Cancer Patients
Preliminary data shows promising efficacy and safety in first-time use for BCG-naive patients.
Feb. 26, 2026
Johnson & Johnson Announces Promising Results for Prostate Cancer Drug Combination
Early study shows pasritamig and docetaxel demonstrate deep PSA responses and favorable safety profile
Feb. 25, 2026
Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 to Treat Recurrent High-Grade Glioma
The designation is intended to facilitate the expedited development and review of SRN-101, recognizing its potential to address a serious condition with significant unmet medical need.
Feb. 24, 2026
Microplastics Found in Majority of Prostate Cancer Tumors
Study reveals concerning presence of common consumer plastics in prostate cancer tissue samples
Feb. 24, 2026
Monte Rosa Therapeutics Presents Positive Phase 1/2 Data for MRT-2359 in Prostate Cancer
Combination with enzalutamide shows 100% PSA response rate in patients with AR mutations
Feb. 24, 2026
Monte Rosa Therapeutics Presents Updated Clinical Data on MRT-2359 in Metastatic Prostate Cancer
Combination with enzalutamide shows promising results in heavily pretreated patients with AR mutations
Feb. 24, 2026
Early Mental Health Disorders Linked to Higher Cancer Mortality
New study finds over 10% of cancer patients develop mental health issues within a year of diagnosis, increasing risk of death
Feb. 24, 2026
Flatiron Health Attends the 2026 American Society of Genitourinary Cancers Symposium to Answer Oncology's Most Critical Questions
New research from prostate and bladder cancer Panoramic datasets offers pathways for optimized patient-centered care
Feb. 23, 2026
Kyntra Bio Announces Positive Data from Prostate Cancer Drug Trial
FG-3246 combination therapy shows promising results in metastatic castration-resistant prostate cancer patients
Feb. 16, 2026
Firefighter Drops Blue Shield to Get Denied Cancer Care
Ken Jones hopes switching to basic Medicare will allow him to receive immunotherapy treatment.
Feb. 13, 2026
HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer
First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer
Feb. 9, 2026
Cancer Patients' Art Featured at SFMOMA in Groundbreaking Exhibition
The 'Art for Recovery' show marks the first time a major museum has displayed artwork created by cancer patients during treatment.
